Advertisement

Combination Therapy in Urological Malignancy

  • Philip H. Smith

Part of the Clinical Practice in Urology book series (PRACTICE UROLOG)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. G. Stoter, C. J. Rodenburg
    Pages 25-28
  3. S. A. Brosman
    Pages 29-49
  4. T. Ebert, R. Ackermann
    Pages 51-81
  5. Cora N. Sternberg, H. I. Scher
    Pages 95-118
  6. M. Pavone-Macaluso
    Pages 143-172
  7. C. J. Rodenburg, G. Stoter
    Pages 191-198
  8. W. G. Jones
    Pages 199-205
  9. B. Goldwasser, J. Ramon, O. Nativ
    Pages 207-223
  10. Sophie D. Fosså, N. K. Aaronson, F. Calais da Silva
    Pages 255-263
  11. D. W. W. Newling, J. Hutton
    Pages 265-274
  12. Back Matter
    Pages 275-278

About this book

Introduction

Any discussion of the present success in management of urological cancers evokes a mixed response. Oncologists and urologists can enjoy the success with chemotherapy for testicular cancers but cannot forget the dismal results with any form of treatment, other than surgery, for renal carcinoma. But these are the less frequent urolegi­ cal tumours: what are the attitudes to the more common prostate and bladder cancers. Intensive study, many clinical trials and much debate lead us to the conclusion that we understand them better, we can tailor the treatment more appropriately to the individual patient but there remains some uncertainty as to the overall success that we have achieved. There have been no striking changes in the 5-year survival data. Clinicians tend to see their success in terms of their special interest. Radiotherapists point to their success in stage-reduction but what are we to do with the many patients whose tumour is unaltered by radiotherapy. Urological surgeons, and especially those who are still influenced by the shadow of Halsted, point to their success in excising the cancer but apart from that highly selected group, what are we to do for the very large number of patients for whom surgery is inappro­ priate. Bystanders can only watch and listen to the arguments for and against these views.

Keywords

Staging Tumor cancer carcinoma chemotherapy clinical trial immunotherapy kidney metastatic disease oncology prostate quality of life radiation radiation therapy surgery

Editors and affiliations

  • Philip H. Smith
    • 1
  1. 1.St James’s University HospitalLeedsUK

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4471-1655-4
  • Copyright Information Springer-Verlag London 1989
  • Publisher Name Springer, London
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4471-1657-8
  • Online ISBN 978-1-4471-1655-4
  • Series Print ISSN 0177-8994
  • Buy this book on publisher's site